Mesa Labs reported a decrease in fourth quarter revenues by 5.6% and an increase in operating income by 570%. The company's performance was influenced by currency headwinds, slower biopharmaceutical spending, and a decrease in COVID-related revenues.
Fourth quarter revenues decreased by 5.6%.
Fourth quarter Non-GAAP core organic revenues decreased by 1.6%.
Fourth quarter operating income increased by 570%.
Fourth quarter Non-GAAP adjusted operating income excluding unusual items decreased by 21.1%.
In fiscal 2024, Mesa Labs is biasing toward conservatism while maintaining its long-term growth outlook, expecting currency headwinds to abate over the course of the year. The company continues to see softness in new systems / CAPEX orders for both the Clinical Genomics and Biopharmaceutical Development divisions.
Visualization of income flow from segment revenue to net income